| 23-788 |
Hope Medical Enterprises, Inc., dba Hope Pharmaceuticals v. Fagron Compounding Services, LLC, et al. |
Ninth Circuit |
2024-01-22 |
Denied |
Response RequestedResponse WaivedRelisted (2) |
circuit-split drug-regulation federal-law federal-preemption food-and-drug-administration preemption state-law state-rights statutory-interpretation |
Whether the FDCA preempts state laws prohibiting the in-state sale of unapproved drugs whose sale is also prohibited as a matter of federal law by the… |
| 23-395 |
Alliance for Hippocratic Medicine, et al. v. Food and Drug Administration, et al. |
Fifth Circuit |
2023-10-16 |
Denied |
Amici (3) |
abortion abortion-medication administrative-procedure-act drug-regulation fda fda-approval generic-drugs medical-safety mifepristone subpart-h |
Whether Cross-Petitioners' challenge to FDA's 2000 mifepristone approval is timely |
| 20-1594 |
Murray Rojas v. United States |
Third Circuit |
2021-05-18 |
GVR |
Amici (1) |
criminal-statute drug-dispensing drug-regulation fdca federal-criminal-law federal-state-balance federalism lenity medical-practitioner statutory-interpretation young-v-united-states |
Whether the FDCA's felony prohibitions on 'dispensing' drugs reach the administering of drugs by practitioners, which has been left to state and local… |
| 20-1264 |
Fusion IV Pharmaceuticals, Inc., dba Axia Pharmaceutical, et al. v. Anne Sodergren |
Ninth Circuit |
2021-03-11 |
Denied |
Response Waived |
commerce-clause compounding-quality-act drug-quality-and-security-act drug-regulation fdca-preemption federal-outsourcing-facilities federal-oversight federal-preemption outsourcing-facilities state-licensing state-licensing-requirements |
Whether 21 U.S.C. §353b preempts California state law licensing requirements |